Expression of interleukin-11 (IL-11) and IL-11 receptor α in human gastric carcinoma and IL-11 upregulates the invasive activity of human gastric carcinoma cells

TOSHIYUKI NAKAYAMA1, AYUMI YOSHIZAKI1, SEIYA IZUMIDA1, TOMOYUKI SUEHIRO1, SHIRO MIURA1, TAKASHI UEMURA1, YUICHI YAKATA1, KAZUKO SHICHIJO1, SHUNICHI YAMASHITA2 and ICHIRO SEKIN1

Departments of 1Tumor and Diagnostic Pathology and 2Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki, Japan

Received August 16, 2006; Accepted November 29, 2006

Abstract. Previous investigations have shown that interleukin-11 (IL-11) and the IL-11 receptor (IL-11R) have been correlated with the regulation of tumor progression, cellular growth and differentiation in several malignant tumors. The objectives of this study were to clarify the role of IL-11 and IL-11R·α in human gastric carcinoma. IL-11 and IL-11R·α were studied in 73 cases of surgically resected human gastric adenocarcinomas by immunohistochemistry. The invasive activity and cell signaling pathway of gastric carcinoma cell lines were also examined. Among the 73 cases of adenocarcinoma, 53 (72.6%) and 47 cases (64.4%) showed positive staining in carcinoma cells for the IL-11 and IL-11R·α proteins, respectively. Histologically, IL-11 expression correlated only with Lauren’s classification (p<0.05). The expression of IL-11R·α correlated with the grade of tumor invasion (p<0.05) and vessel infiltration (p<0.01). All of the four gastric carcinoma cell lines expressed both IL-11 and IL-11R·α proteins in Western blot analysis. Recombinant human IL-11 (rhIL-11) promoted the migration of SCH cells by the activation of the phosphatidylinositol-3 kinase pathway. Wortmannin diminished the promotion of chemotactic motility and invasive activity by rhIL-11. These findings suggest that the IL-11/IL-11R pathway plays an important role in the progression and the differentiation of human gastric carcinomas.

Introduction

Gastric cancer is one of the most common cancer types in the world today, in spite of the fact that its incidence has shown a gradual decline in many countries (1). The occurrence and progression of cancer is considered to be a series of genetic events affecting the structure and/or expression of a number of oncoproteins, anti-oncoproteins and growth factors (2,3). The deep invasive carcinomas, as in gastric carcinoma, have higher rates of lymph duct and venous invasion and lymph node metastasis (4). However, the mechanism of invasion and metastasis of gastric carcinoma is not fully understood.

Interleukin-11 (IL-11) was initially cloned as a mediator of plasmacytoma cell proliferation (5) and was later found to exhibit a wide variety of biological effects in neural cells as well as in the hematopoietic and the immune systems (6). Various unique biological functions have been attributed to IL-11, although it shares gp130 as a signaling mechanism with several cytokines and growth factors, including IL-6, oncostatin M, leukemia inhibitory factor (LIF), and ciliary neurotrophic factor (CNTF) (7).

The IL-11 receptor (IL-11R) mediates the action of IL-11, a 19.1-kDa pleiotropic cytokine that was initially cloned from a bone-marrow stromal cell line (5). While the hematopoietic effects of IL-11, which include stimulation of megakaryocyte maturation and platelet production (6), and growth stimulation of CD34+ hematopoietic progenitor cells (8), have been well studied, IL-11R has also been shown to mediate the inhibition of adipogenesis (8), stimulation of osteoclasts (9), and cytoprotection of gut mucosa (10-13). The α subunit of IL-11R (IL-11Rα) is required for high affinity binding of the ligand; on ligand binding, gp130, the subunit responsible for signal transduction, is required for the receptor complex (14). It is not known whether IL-11Rα associated with gp130 undergoes homodimerization, as it does in the case of the IL-6 receptor, or if an additional, as yet unidentified, subunit is involved (15).

The nature of the signaling transduction systems used by IL-11R is currently under investigation. Protein kinases that have been implicated in IL-11-mediated signaling include Jak1 and Jak2 receptor-associated kinases (15-17), MAP kinase (MAPK) and the ribosomal S6 protein kinase (18), src-family tyrosine kinases including p60c and p62src, and phosphatidylinositol-3 kinase (PI3K) (19,20). There is also

Correspondence to: Dr Toshiyuki Nakayama, Department of Tumor and Diagnostic Pathology, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan E-mail: toshi-n@nagasaki-u.ac.jp

Key words: interleukin-11, interleukin-11 receptor, phosphatidylinositol-3 kinase, gastric cancer
evidence that the signal transduction and transcription factors (STAT) 1 and STAT3 are activated by IL-11R (15,21).

In this study, the expression of IL-11 and the IL-11Rα was examined in primary human gastric adenocarcinomas. Studies were also carried out on gastric carcinoma cell lines aimed at determining the biologic functions of IL-11.

Materials and methods

Clinical materials. Normal gastric mucosa was obtained from a patient at autopsy. Tumor specimens were obtained from patients operated on at Nagasaki University Hospital between 1999 and 2004. Each tumor was assigned a histological type and a depth grading of infiltration according to the Lauren, Carneiro and Goseki classification (22,23) and the Japanese Classification of Gastric Carcinoma by the Japanese Research Society for Gastric Cancer (24), based on World Health Organization classification (25). There were 73 primary human gastric adenocarcinomas, which were composed of: 19 mucosal carcinomas, 18 submucosal infiltrative carcinomas, 7 carcinomas invading proprial muscle layers, 8 carcinomas reaching the subserosa, and 20 carcinomas penetrating the serosal surface. Histologically, of the 73 primary human gastric adenocarcinomas, 3 were papillary adenocarcinomas, 14 were tubular adenocarcinomas of the well-differentiated type, 25 were tubular adenocarcinomas of the moderately differentiated type, 6 were poorly differentiated adenocarcinomas of the solid type, 11 were poorly differentiated adenocarcinomas of the non-solid type, 11 were signet-ring cell carcinomas and 3 were mucinous adenocarcinomas. There were four adenomas included as benign lesions with moderate dysplasia. Fifteen specimens of normal gastric mucosal tissue were evaluated as normal controls that were obtained from normal areas adjacent to where the tumor specimens were taken. The desmoplastic stromal reaction was graded according to the extent of the stromal area involved. It was defined as ‘slight’ when the fibrous stromal area was <25% of the whole tumor, ‘moderate’ (between 25 and 50%), and ‘extensive’ (when it exceeded 75% of the whole tumor) based on the overall pattern (26). The examination was performed on routine slides to identify lymphatic, venous and perineural invasion. Hematoxylin and eosin and the van Gieson elastic staining methods were used in all cases. Each parameter was defined as ‘present’ when invasion was identified with certainty, but defined as ‘absent’ when it was either not observed at all or not observed with certainty (27,28). Lymph node metastasis was defined as ‘present’ only when histologically proven. Diagnosis was established by two independent pathologists (T. Nakayama and I. Sekine). IL-11 and IL-11Rα expression was classified into three categories depending on the percentage of cells stained: -, 0-10% positive cells; +, 10-50% positive tumor cells; and ++, >50% positive tumor cells.

Reagents and cell culture. Recombinant human IL-11 (rhIL-11) was kindly provided by Yamanouchi Pharmaceutical Co., Ltd. (Tokyo, Japan) and was diluted in cell culture medium. MKN-1, MKN-28, NUGC-3 and SCH cell lines derived from human gastric cancer were obtained from the Human Health Resources Bank (Osaka, Japan). All cell lines were maintained in RPMI-1640 (Invitrogen Corp., Carlsbad, CA, USA) supplemented with heat inactivated 10% fetal calf serum (FCS, Invitrogen Corp.) and 2 mM glutamine (Invitrogen Corp.) and incubated at 37°C in a humidified atmosphere containing 5% CO2.

Stimulations and inhibitions. The cells were first starved in medium with reduced serum for 24 h to reduce basal levels of the phosphorylated(p)-S6 ribosomal protein, p-p90 RSK or p-p38 MAPK before stimulation and then were stimulated with 25, 50 and 100 ng/ml recombinant human IL-11 (Yamanouchi Pharmaceutical Co., Ltd.) for all experiments. The inhibitor Wortmannin (100 nM, Sigma-Aldrich, St. Louis, MO, USA) was added 30 min prior to IL-11 stimulation. The inhibitors were dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich). A DMSO concentration of 0.001% was tested on each cell and no change in function was detected when compared to untreated cells.

Western blot analysis. Western blot analysis was performed on human gastric carcinoma tissues and human gastric carcinoma cell lines. The tissues obtained at surgery were frozen immediately after tissue sampling. The tissues and the cells were then suspended in RIPA buffer (50 mM Tris, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate and 0.05% SDS, pH 7.4), broken into pieces on ice and subjected to three freeze-thaw cycles. The insoluble tissue debris was removed by centrifugation at 14,000 x g at 0°C for 10 min. The cell pellets were lysed in lysis RIPA buffer containing 50 mM Tris, 150 mM NaCl, 1% NP40 and 0.25% sodium deoxycholate. The cells were then cleared by centrifugation at 14,000 x g at 0°C for 10 min and sample buffer was added. The supernatant was collected and the protein concentration was quantified using a protein assay reagent (Bio-Rad Laboratories, Hercules, CA, USA). After boiling, the proteins (20 μg) were separated by polyacrylamide gel electrophoresis (PAGE) under denaturing and reducing conditions, and transferred...
to a Hybond ECL nitrocellulose membrane (Amersham Pharmacia Biotech, Arlington Height, IL). The membranes were rinsed in TBS, blocked with 5% low-fat dried milk in TBS containing 0.1% Tween-20 (TBS-T), and then incubated for 1 h at room temperature with a 1:500 dilution of the anti-human IL-11 or IL-11R antibody (Santa Cruz Biotechnology, Inc.) and with a 1:1,000 dilution of the p-S6 ribosomal protein (Ser235/236), p-p90 RSK (Ser380) or p-p38 MAPK (Thr180/Tyr182) antibodies (Cell Signaling Technology, Beverly, MA, USA). The anti-human β-tubulin antibody (Santa Cruz Biotechnology, Inc.) was used as an indicator for the amount of loading proteins. After extensive washing with TBS-T, the membranes were incubated for 1 h with a 1:1,000 dilution of the horseradish-peroxidase-conjugated donkey anti-rabbit immunoglobulin G (Santa Cruz Biotechnology, Inc.) in TBS-T containing 3% low-fat dried milk. The membranes were washed and developed with a horseradish peroxidase chemiluminescence detection reagent (ECL Plus System, Amersham Pharmacia Biotech), and then exposed to Hyperfilm ECL (Amersham Pharmacia Biotech).

Cell growth. The cells were seeded in 6-well dishes (Corning Inc., Corning, NY, USA) at 1x10^4 cells per well and cultured in RPMI-1640 containing 0.5% FCS with/without the presence of rhIL-11 (50 ng/ml, Yamanouchi Pharmaceutical Co., Ltd.). Normal rabbit IgG at the same concentration was used as a control for IL-11. To examine growth stimulation by IL-11, the medium was changed every 2 days and the number of cells and viability were counted every 2 days using a conventional improved Neubauer hemocytometer (Bright-Line; American Optical Corp. Buffalo, NY, USA). A single, experienced technologist was responsible for all manual cell counting (29).

Migration/chemotaxis assay. A 0.1-ml aliquot of SCH cell suspension at 1x10^5 cells/ml was seeded on the upper chamber of transwell filters (8-μm pore) (Corning Inc.), which was transferred to wells containing buffer with rhIL-11 protein or wortmannin. FCS-containing medium was added to the lower chamber and incubated for 18 h at 37°C. Non-migrating cells that remained on the upper surface of the filter were removed, and the migrated cells on the lower surface of the filter were fixed with 100% methanol and stained. Five different fields were counted with a light microscope (Nikon E400) at magnification x200. All assays were performed in triplicate.

Matrigel invasion assay. The Matrigel invasion assay was carried out according to the manufacturer's instructions (BD Biosciences, Palo Alto, CA, USA). A 0.5-ml aliquot of SCH cell suspension at 1x10^5 cells/ml was seeded on the upper chamber of Matrigel-coated transwell filters (8-μm pore) which were transferred to wells containing buffer with rhIL-11 protein, FCS or wortmannin. Preliminary experiments showed that no cytotoxicity occurred at these concentrations as inspected under the microscope or by the trypan blue exclusion test. Control cultures received only the vehicle (0.001% DMSO). Conditioned medium without serum was added to the lower chamber and incubated for 72 h. Non-invading cells that remained on the upper surface of the filter were removed, and the cells that appeared on the lower surface of the filter were fixed with 100% methanol, stained and counted as described for the migration/chemotaxis assay. Each assay was carried out in triplicate.

Statistical analysis. The StatView II program (Abacus Concepts, Inc., Berkeley, CA, USA) was used for statistical analyses. Analyses comparing the degrees of IL-11 or IL-11R expression were performed by the Mann-Whitney and Spearman tests.

Results

Expression of IL-11 and IL-11Rα in human gastric carcinoma tissue. The IL-11 protein was localized in the cytoplasm (Fig. 1A), while IL-11Rα protein was localized in the membrane and the cytoplasm of cancer cells (Fig. 1B). In IL-11Rα expression, the invasive parts of the primary tumor were intensely stained when compared with the superficial parts of the tumor in almost all cases of invasive carcinomas. However, there was no specific distribution of IL-11 expression in invasive carcinoma tissue. In many cases, both IL-11 and IL-11R were expressed in the carcinoma cell itself.

The immunohistochemical results are summarized in Tables I and II. IL-11 and IL-11Rα were expressed in human
gastric adenocarcinoma and adenoma. Normal gastric epithelium and fibroblast and endothelial cells in the stroma of tumors expressed IL-11 and IL-11R, although weakly. Among 10 cases of adenoma, 8 (80.0%) expressed IL-11 protein. IL-11 positive staining occurred mainly in the cytoplasm. Only two cases (20.0%) of adenoma showed positive staining for IL-11R in the cell membranes. The difference of IL-11R expression between adenoma and adenocarcinoma was significant (p=0.003054).

Histologically, the expression of IL-11 and IL-11R was variable (Tables I and II). Signet-ring cell carcinomas revealed significantly lower expression of IL-11 than the other histological types (p=0.03360). In Lauren’s classification, the expression of IL-11 was statistically higher in the intestinal type of adenocarcinomas than in the diffuse type of adenocarcinomas (p=0.04952). For IL-11 expression, there were no correlations in the other factors. Gastric carcinoma cells showed a statistical correlation with IL-11R expression in the depth of invasion (p=0.01028) and the venous invasion (p=0.006219) (Tables I and II). No other correlations with other clinicopathological factors were detected for the expression of IL-11R in gastric carcinomas.

**Western blot analyses of IL-11 and IL-11Rα in human normal and gastric carcinoma tissues.** The expression of the IL-11 protein, its receptor and the activation of signaling proteins in gastric carcinoma tissues were examined by Western blot analysis. The IL-11 protein was clearly detected in all of the four cases of both human gastric carcinomas and normal mucosal tissues (Fig. 2). In each of the four cases, IL-11 and gp130 protein were expressed in normal and carcinoma tissues. There was no difference in the level of expression between the normal and carcinoma tissues. IL-11R was expressed both in normal and carcinoma tissues. There was no difference in the level of expression between the normal and carcinoma tissues. IL-11Rα was expressed both in normal and carcinoma tissues. IL-11Rα, p-S6-ribosomal protein and p-P38 MAPK in cases 2-4 and p-P90 RSK in cases 2 and 3 were more highly expressed in carcinoma tissues than in normal tissues.

**Expression of IL-11, IL-11Rα and gp130 in gastric carcinoma cell lines.** The expression of IL-11 protein by gastric carcinoma cell lines...
cell lines was examined by Western blot analysis. The IL-11 protein was clearly detected in all of the four human gastric carcinoma cell lines at various levels (Fig. 3). MKN-1, MKN-28 and NUGC-3 cells expressed IL-11 at high levels, while SCH cell expressed IL-11 at a relatively low level. All four gastric carcinoma cell lines expressed IL-11R and gp130 protein.

Effects of rhIL-11 on cell growth of gastric carcinoma cell lines. The effect of exogeneous IL-11 on the growth of gastric carcinoma cells was examined. MKN-28 and SCH cells were stimulated by four different doses of rhIL-11 protein. The counts of MKN28 cells revealed a progressive growth with every dose of rhIL-11 protein until the 4th day. After the 6th day, the cell numbers gradually declined and became stable (Fig. 4A). In SCH cells, the cell numbers with each dose of rhIL-11 steadly increased until the 12th day (Fig. 4B). However, there was no statistical difference in the cell growth whether the cell was treated by rhIL-11 or not in both MKN-28 and SCH cells.

Table II. IL-11/IL-11R expression in invasive carcinoma (53 cases), n (%).

<table>
<thead>
<tr>
<th></th>
<th>IL-11</th>
<th></th>
<th>IL-11R</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>-</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>invasive carcinoma</td>
<td>53</td>
<td>15(28.3)</td>
<td>7(13.2)</td>
<td>31(58.5)</td>
</tr>
<tr>
<td>desmoplastic stromal reaction</td>
<td>n.s.</td>
<td></td>
<td></td>
<td>n.s.</td>
</tr>
<tr>
<td>slight</td>
<td>8</td>
<td>0 (0.0)</td>
<td>1 (12.5)</td>
<td>7 (87.5)</td>
</tr>
<tr>
<td>moderate</td>
<td>25</td>
<td>7 (28.0)</td>
<td>4 (16.0)</td>
<td>14 (56.0)</td>
</tr>
<tr>
<td>extensive</td>
<td>20</td>
<td>8 (40.0)</td>
<td>2 (10.0)</td>
<td>10 (50.0)</td>
</tr>
<tr>
<td>tumor growth pattern</td>
<td>n.s.</td>
<td></td>
<td></td>
<td>n.s.</td>
</tr>
<tr>
<td>expansive</td>
<td>9</td>
<td>2 (22.2)</td>
<td>2 (22.2)</td>
<td>5 (55.6)</td>
</tr>
<tr>
<td>intermediate</td>
<td>21</td>
<td>5 (23.8)</td>
<td>2 (9.5)</td>
<td>14 (66.7)</td>
</tr>
<tr>
<td>infiltrative</td>
<td>23</td>
<td>8 (34.8)</td>
<td>3 (13.0)</td>
<td>12 (52.2)</td>
</tr>
<tr>
<td>lymphatic invasion</td>
<td>n.s.</td>
<td></td>
<td></td>
<td>n.s.</td>
</tr>
<tr>
<td>present</td>
<td>42</td>
<td>12 (28.6)</td>
<td>4 (9.5)</td>
<td>26 (61.9)</td>
</tr>
<tr>
<td>absent</td>
<td>11</td>
<td>3 (27.3)</td>
<td>3 (27.3)</td>
<td>5 (45.5)</td>
</tr>
<tr>
<td>venous invasion</td>
<td>n.s.</td>
<td></td>
<td></td>
<td>p=0.006219</td>
</tr>
<tr>
<td>present</td>
<td>33</td>
<td>9 (27.3)</td>
<td>3 (9.1)</td>
<td>21 (63.6)</td>
</tr>
<tr>
<td>absent</td>
<td>20</td>
<td>6 (30.0)</td>
<td>4 (20.0)</td>
<td>10 (50.0)</td>
</tr>
</tbody>
</table>

n.s., not significant.

Figure 2. Expression of IL-11, IL-11R, gp130 and activated signaling proteins in human gastric carcinoma tissues. IL-11 and gp130 protein were expressed in gastric carcinoma and normal tissues. There was no difference in the expression level between normal and carcinoma tissues. IL-11R, p-S6-ribosomal protein and p-P38 MAPK in cases 2, 3 and 4 and p-P90 RSK in cases 2 and 3 were more highly expressed in carcinoma tissues than in normal tissues. Lane 1, case 1-normal mucosa; lane 2, case 1-carcinoma; lane 3, case 2-normal mucosa; lane 4, case 2-carcinoma; lane 5, case 3-normal mucosa; lane 6, case 3-carcinoma; lane 7, case 4-normal mucosa; lane 8, case 4-carcinoma.

Figure 3. Expression of IL-11, IL-11R, and gp130 in human gastric carcinoma cell lines. The IL-11 protein was detected in all four human gastric carcinoma cell lines. MKN-1, MKN-28 and NUGC-3 cells expressed IL-11 at high levels, while SCH cell expressed IL-11 at a relatively low level. All four gastric carcinoma cell lines expressed IL-11R and gp130 protein. Lane 1, MKN-1; lane 2, MKN-28; lane 3, NUGC-3; lane 4, SCH.

Chemoataxis assays of human gastric carcinoma cells in response to rhIL-11. Transwell migration assays were performed to examine the mobilizing effect of rhIL-11 on.
MKN28 and SCH gastric carcinoma cells. Fig. 5 shows the chemotactic response of gastric carcinoma cells to various concentrations of rhIL-11. Compared with MKN28 cells (Fig. 5A), SCH cells exhibited significant and dose-dependent chemotactic responses to rhIL-11 up to 50 ng/ml in different FCS concentrations (Fig. 5B). However, the chemotactic response to 100 ng/ml of rhIL-11 was almost the same as to 50 ng/ml of rhIL-11 in SCH cells.

Activation of signal transduction elements in response to rhIL-11 stimulation. As a first step in defining the IL-11 signaling pathway, the phosphorylation of p90RSK, p38 MAPK and S6 ribosomal protein PI3K by IL-11 was determined. The cells were stimulated with 50 ng/ml of rhIL-11 for 5 min (Fig. 6). In the two gastric carcinoma cell lines, SCH and MKN-28, different reactions to signaling activation were noted. The p38MAPK was faintly phosphorylated in unstimulated cells, and rhIL-11 did not influence its phosphorylation state (Fig. 6B). However, the chemotactic response to 100 ng/ml of rhIL-11 was almost the same as to 50 ng/ml of rhIL-11 in SCH cells.

Chemotaxis assay in SCH treated with rhIL-11 and wortmannin. To study the effect of IL-11 on the PI3K pathway in SCH, the chemotactic response was investigated. Wortmannin, a PI3K inhibitor, suppressed chemotactic responses in SCH cells. The number of cells undergoing chemotaxis through a reconstituted basement membrane per five different fields is shown in Fig. 7. The 50 ng/ml of rhIL-11 upregulated the chemotactic activity of SCH cells by as much as three-fold over the non-treated cells. Treatment with 100 nM of wortmannin clearly reduced the promotive effect of rhIL-11 in the chemotaxis assay.

Invasion assay in SCH treated with rhIL-11 and wortmannin. An in vitro invasion assay was performed to investigate the effects of these chemotactic responses on the invasiveness of gastric carcinoma cells. Fig. 8 shows the number of cells that invaded through a reconstituted basement membrane per five different fields. SCH cells exhibited highly invasive responses, in a dose-dependent fashion, to rhIL-11 through the reconstituted basement membrane. To study the effect
of IL-11 on the PI3K pathway in SCH cells, the effect of wortmannin, a PI3K inhibitor, on the invasive response was studied. The results showed a suppression of the chemotactic response in SCH cells (Fig. 8).

**Wortmannin suppressed PI3K phosphorylation of gastric carcinoma cell line.** To study the effect of wortmannin on the PI3K pathway in gastric carcinoma cells, SCH cells were preincubated with wortmannin. Phosphorylation of S6 ribosomal protein was induced by the stimulation of rhIL-11 (Fig. 8). However, wortmannin, an inhibitor of PI3K, inhibited the phosphorylation of S6 ribosomal protein in SCH cells.

These findings suggested that IL-11 might play an important role in migration and invasion, mediated through its signaling pathway, in gastric cancer cells.

**Discussion**

The expression of IL-11 has been reported in many types of cells, such as fibroblasts, chondrocytes, synovial epithelium, bronchial epithelium, and colonic epithelium (30-33). Human IL-11 has been shown to have a pleiotropic action on hematopoietic, hepatic, stromal, epithelial, neural, and osteoclast cells (34). The studies reported here demonstrate for the first time the expression of the IL-11R protein in human gastric mucosa, and in gastric cancer tissues and cell lines. Also demonstrated was the constitutive expression of the IL-11 protein and the co-expression of the signal-transducing subunit gp130 in gastric carcinoma cell lines and freshly isolated gastric cancer tissues. In this study, IL-11 and IL-11Rα were both expressed in the carcinoma cells. Therefore, the tumor cell should respond to IL-11 in an autocrine and/or paracrine fashion to stabilize itself and IL-11 may promote the invasion and the growth of tumors.

IL-11R may play a role in the invasive property of gastric carcinomas because there was a significant correlation between...
IL-11Rα expression and invasive grade (p=0.01029). In those cases where the presence of venous invasion was noted, IL-11Rα was more highly expressed (p=0.006219). It appears that gastric carcinoma and its demonstrated invasive properties are consistent with what has been conceptualized in multistep carcinogenesis, a generally accepted theory with respect to cancer metastasis (35). The results reported here suggest that IL-11 has a role in stromal and venous invasion of gastric carcinoma, and constitutes one of the steps in carcinogenesis and in the development of invasive characteristics.

Histologically, the diffuse type of adenocarcinomas, which showed invasive spread, had a significantly poorer prognosis than the intestinal type (36,37). In this study, a significant correlation was observed between IL-11 expression and histological differentiation of human gastric carcinoma. However, our results detected no association between IL-11R expression and tumor differentiation. Thus, our results reinforced the idea that IL-11 might play an important role in the differentiation of gastric adenocarcinoma.

IL-11R was shown to be functional, since stimulation with its cognate ligand IL-11 induced PI3K and MAPK signaling. IL-11 stimulation was followed by a rapid and transient tyrosine phosphorylation of PI3K or MAPK in the cells analyzed. Since the S6 ribosomal protein and p90RSK proteins were phosphorylated, entered the nucleus, and induced transcription of target genes (7,38), signaling via the PI3K and MAPK pathways was a key event in IL-11-mediated gene regulation and downstream effects. Our data are consistent with the idea that IL-11-induced activation of signaling pathways regulates the expression of a different set of genes, depending on the cell type investigated.

The MAPK pathway is mostly known to be involved in cellular proliferation (39), although several groups have stated that in some cell types it could also be involved in cell migration (40-42). The PI3K pathway is said to be an anti-apoptotic pathway in myeloma (43) although numerous groups have found that PI3K plays a key role in migration and gradient-sensing in other cell types (44-47). In our study, wortmannin, an inhibitor of the PI3K pathway, suppressed the phosphorylation of S6 ribosomal protein and reduced the invasive activity of a gastric carcinoma cell line. Thus, the activation of PI3K pathway by IL-11 may play an important role in the invasive behavior of gastric carcinoma cells.

IL-11 is known as the activator of the Jak/STAT pathway (15,21). The expression of phosphorylated STATs was studied in two types of gastric carcinoma cell lines. Stimulation with IL-11 in the two cell lines resulted in only a transient phosphorylation of STATs (data not shown). However, these cell lines were different only in the nature of invasive activity. Therefore, it was concluded that the activation of the Jak/STAT pathway did not play an important role in the invasion of gastric carcinoma cells.

Recombinant human interleukin-11 (rHuIL-11, Oprelvekin, Neumega®) was the first commercially available thrombopoietic cytokine (48). Some reports showed that IL-11 therapy suppressed the symptoms of diarrhea, normalized myeloperoxidase activity, and healed mucosal injury in animal models (49-51). And one report of IL-11 treatment showed the suppressive effect to the symptoms of patients with Crohn’s disease (52). Though this constitutes a salutary effect of IL-11, rhIL-11 has significant side effects (53). In this study, rhIL-11 upregulated the invasive activity of carcinoma cells. While some of the data described here on IL-11 presents intriguing possibilities, considerably more progress must be made before entertaining the idea of using rhIL-11 for therapy against inflammatory bowel disease.

In conclusion, we demonstrated that the IL-11/IL-11R system regulated the activation of PI3K and MAPK pathways and upregulated the invasive activity of gastric carcinoma cells. Further identification of tyrosine kinases and/or the other pathway by IL-11 is needed to fully understand the role of this cytokine in the invasive behavior of gastric carcinoma cells.

Acknowledgements

We are grateful to Mr. Toshiyuki Kawada (Nagasaki University Graduate School of Biomedical Sciences) for his excellent immunohistochemical and molecular biological assistance.

References


